Literature DB >> 22138805

The role of prophylactic antimicrobials during autologous stem cell transplantation: a single-center experience.

B S Sohn1, D H Yoon, S Kim, K Lee, E H Kang, J S Park, D H Lee, S H Kim, J Huh, C Suh.   

Abstract

The aim of this study was to investigate the efficacy of antibiotic prophylaxis in patients undergoing autologous stem cell transplantation (ASCT) for multiple myeloma and non-Hodgkin lymphoma. Among 232 ASCT cases performed at the Asan Medical Center, 114 cases underwent treatment with ciprofloxacin, fluconazole, and acyclovir (between January 2001 and August 2005), while 118 cases were performed without antimicrobial prophylaxis (between February 2004 and June 2008). The two-rate χ2 test was applied to accommodate the differences in neutropenia duration. The incidence of febrile episodes was 9.8 cases per 100 person-days in the prophylactic group, while it was 16.2 cases in the no-prophylactic group (p<0.001). The rate of unexplained fever was 8.0 cases per 100 person-days in the prophylactic group, while it was 13.8 cases in the no-prophylactic group (p<0.001). The rate of clinically and microbiologically documented infection was 1.7 cases per 100 person-days in the prophylactic group, while it was 2.3 cases in the no-prophylactic group (p=0.404). There were fewer cases of methicillin-susceptible Staphylococcus aureus infection and a greater number of quinolone-resistant Escherichia coli in the prophylactic group compared with the no-prophylactic group (p=0.056 and p=0.040, respectively). The prophylactic antimicrobials reduced the incidence rate of febrile episodes, especially unexplained fever, despite there being no difference in the incidence of documented infection. Resistant microbe infection occurred more frequently in the prophylactic group.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22138805     DOI: 10.1007/s10096-011-1489-2

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  36 in total

1.  Practices of infectious disease prevention and management during hematopoietic stem cell transplantation: a survey from the European group for blood and marrow transplantation.

Authors:  W H Krüger; R J Hornung; B Hertenstein; W V Kern; N Kröger; P Ljungman; A R Zander
Journal:  J Hematother Stem Cell Res       Date:  2001-12

2.  2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.

Authors:  Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young
Journal:  Clin Infect Dis       Date:  2002-02-13       Impact factor: 9.079

3.  The use and interpretation of quasi-experimental studies in infectious diseases.

Authors:  Anthony D Harris; Douglas D Bradham; Mona Baumgarten; Ilene H Zuckerman; Jeffrey C Fink; Eli N Perencevich
Journal:  Clin Infect Dis       Date:  2004-05-12       Impact factor: 9.079

Review 4.  Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond.

Authors:  K M Sullivan; C A Dykewicz; D L Longworth; M Boeckh; L R Baden; R H Rubin; K A Sepkowitz
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2001

5.  Prophylactic antibiotics eliminate bacteremia and allow safe outpatient management following high-dose chemotherapy and autologous stem cell rescue.

Authors:  B Meisenberg; R Gollard; T Brehm; R McMillan; W Miller
Journal:  Support Care Cancer       Date:  1996-09       Impact factor: 3.603

6.  Patients with malignant lymphomas experience a higher rate of documented infections than patients with breast cancer after high-dose chemotherapy with autologous peripheral stem cell transplantation.

Authors:  O Sezer; J Eucker; C Bauhuis; M Schweigert; D Lüftner; U Kalus; E Späth-Schwalbe; R Arnold; K Possinger
Journal:  Ann Hematol       Date:  2000-11       Impact factor: 3.673

7.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

8.  Early infectious complications in autologous bone marrow transplantation: a review of 219 patients.

Authors:  S B Mossad; D L Longworth; M Goormastic; J M Serkey; T F Keys; B J Bolwell
Journal:  Bone Marrow Transplant       Date:  1996-08       Impact factor: 5.483

Review 9.  Antimicrobial prophylaxis in bone marrow transplantation.

Authors:  F Momin; P H Chandrasekar
Journal:  Ann Intern Med       Date:  1995-08-01       Impact factor: 25.391

10.  Activity of quinolones against viridans group streptococci isolated from blood cultures of patients with haematological malignancy.

Authors:  K G Kerr; H T Armitage; P H McWhinney
Journal:  Support Care Cancer       Date:  1999-01       Impact factor: 3.603

View more
  5 in total

1.  Fluoroquinolone prophylaxis in autologous hematopoietic stem cell transplant recipients.

Authors:  Dipenkumar Modi; Hyejeong Jang; Seongho Kim; Malini Surapaneni; Kamya Sankar; Abhinav Deol; Lois Ayash; Divaya Bhutani; Lawrence G Lum; Voravit Ratanatharathorn; Richard Manasa; Kendra Mellert; Pranatharthi Chandrasekar; Joseph P Uberti
Journal:  Support Care Cancer       Date:  2017-04-02       Impact factor: 3.603

2.  The Dutch Working Party on Antibiotic Policy (SWAB) Recommendations for the Diagnosis and Management of Febrile Neutropenia in Patients with Cancer.

Authors:  J R de la Court; A H W Bruns; A H E Roukens; I O Baas; K van Steeg; M L Toren-Wielema; M Tersmette; N M A Blijlevens; R A G Huis In 't Veld; T F W Wolfs; W J E Tissing; Y Kyuchukova; J Heijmans
Journal:  Infect Dis Ther       Date:  2022-10-14

3.  Advanced POEMS syndrome treated with high-dose melphalan followed by autologous blood stem cell transplantation: a single-center experience.

Authors:  Il-Young Jang; Dok Hyun Yoon; Shin Kim; Kyoungmin Lee; Kwang-Kuk Kim; Young-Min Lim; Won-Ki Min; Cheolwon Suh
Journal:  Blood Res       Date:  2014-03-24

4.  Clinical impact of fluoroquinolone-resistant Escherichia coli in the fecal flora of hematological patients with neutropenia and levofloxacin prophylaxis.

Authors:  Yong Chong; Shinji Shimoda; Hiroko Yakushiji; Yoshikiyo Ito; Takatoshi Aoki; Toshihiro Miyamoto; Tomohiko Kamimura; Nobuyuki Shimono; Koichi Akashi
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

5.  Incomplete recovery of the fecal flora of hematological patients with neutropenia and repeated fluoroquinolone prophylaxis.

Authors:  Yong Chong; Shinji Shimoda; Noriko Miyake; Takatoshi Aoki; Yoshikiyo Ito; Tomohiko Kamimura; Nobuyuki Shimono
Journal:  Infect Drug Resist       Date:  2017-06-27       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.